Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (1-10 of 247) with videos related to

Pageof 25
Sort By:
Cancer Discovery|July 8, 2017
Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the DarknessJordi Rodon, Josep Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2021
Taking Aim at the UndruggableNiamh Coleman, Jordi Rodon
Current Opinion in Oncology|March 16, 2013
Biomarker-driven patient selection for early clinical trialsRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
The Oncologist|October 19, 2013
Pilot studies for personalized cancer medicine: focusing on the patient for treatment selectionLeticia De Mattos-Arruda, Jordi Rodon
Handbook of Clinical Neurology|March 8, 2016
Principles of pharmacotherapyTracy Batchelor, Jordi Rodon, Manmeet Ahluwalia
Seminars in Oncology|November 29, 2015
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid TumorsCinta Hierro, Jordi Rodon, Josep Tabernero
The Oncologist|January 19, 2010
Combining targeted therapies: practical issues to consider at the bench and bedsideJordi Rodon, Jose Perez, Razelle Kurzrock
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategiesRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Molecular Oncology|August 2, 2014
Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the testRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Expert Opinion on Investigational Drugs|December 5, 2008
Development of PARP inhibitors in oncologyJordi Rodon, Maria D Iniesta, Kyriakos Papadopoulos
Pageof 25

Showing results (1-10 of 247) with videos related to

Sort By:
Pageof 25
Cancer Discovery|July 8, 2017
Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the DarknessJordi Rodon, Josep Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2021
Taking Aim at the UndruggableNiamh Coleman, Jordi Rodon
Current Opinion in Oncology|March 16, 2013
Biomarker-driven patient selection for early clinical trialsRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
The Oncologist|October 19, 2013
Pilot studies for personalized cancer medicine: focusing on the patient for treatment selectionLeticia De Mattos-Arruda, Jordi Rodon
Handbook of Clinical Neurology|March 8, 2016
Principles of pharmacotherapyTracy Batchelor, Jordi Rodon, Manmeet Ahluwalia
Seminars in Oncology|November 29, 2015
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid TumorsCinta Hierro, Jordi Rodon, Josep Tabernero
The Oncologist|January 19, 2010
Combining targeted therapies: practical issues to consider at the bench and bedsideJordi Rodon, Jose Perez, Razelle Kurzrock
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategiesRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Molecular Oncology|August 2, 2014
Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the testRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Expert Opinion on Investigational Drugs|December 5, 2008
Development of PARP inhibitors in oncologyJordi Rodon, Maria D Iniesta, Kyriakos Papadopoulos
Pageof 25